144 related articles for article (PubMed ID: 21756855)
1. Gaps in the achievement of effectiveness of HCV treatment in national VA practice.
Kramer JR; Kanwal F; Richardson P; Mei M; El-Serag HB
J Hepatol; 2012 Feb; 56(2):320-5. PubMed ID: 21756855
[TBL] [Abstract][Full Text] [Related]
2. Rates and predictors of response to anti-viral treatment for hepatitis C virus in HIV/HCV co-infection in a nationwide study of 619 patients.
Ioannou GN; Scott JD; Yang Y; Green PK; Beste LA
Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1373-84. PubMed ID: 24127691
[TBL] [Abstract][Full Text] [Related]
3. Predictors of response of US veterans to treatment for the hepatitis C virus.
Backus LI; Boothroyd DB; Phillips BR; Mole LA
Hepatology; 2007 Jul; 46(1):37-47. PubMed ID: 17567830
[TBL] [Abstract][Full Text] [Related]
4. Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study.
Yee HS; Currie SL; Tortorice K; Cozen M; Shen H; Chapman S; Cunningham F; Monto A
Dig Dis Sci; 2011 Aug; 56(8):2439-48. PubMed ID: 21633833
[TBL] [Abstract][Full Text] [Related]
5. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
Hartwell D; Jones J; Baxter L; Shepherd J
Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
[TBL] [Abstract][Full Text] [Related]
6. [Durability of a sustained virologic response in combination therapy with interferon/peginterferon and ribavirin for chronic hepatitis C].
Kim CH; Park BD; Lee JW; Kim YS; Jeong S; Lee DH; Kim HG; Shin YW; Kwon KS; Lee JI
Korean J Hepatol; 2009 Mar; 15(1):70-9. PubMed ID: 19346787
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].
Husa P; Slesinger P; Stroblová H; Svobodník A; Husová L
Klin Mikrobiol Infekc Lek; 2008 Apr; 14(2):67-73. PubMed ID: 18756436
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.
Zeuzem S; Buti M; Ferenci P; Sperl J; Horsmans Y; Cianciara J; Ibranyi E; Weiland O; Noviello S; Brass C; Albrecht J
J Hepatol; 2006 Jan; 44(1):97-103. PubMed ID: 16290907
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.
Mach TH; Cieśla A; Warunek W; Janas-Skulina U; Cibor D; Owczarek D; Ciećko-Michalska I
Pol Arch Med Wewn; 2011 Dec; 121(12):434-9. PubMed ID: 22157768
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
11. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response.
Carlsson T; Reichard O; Norkrans G; Bläckberg J; Sangfelt P; Wallmark E; Weiland O
J Viral Hepat; 2005 Sep; 12(5):473-80. PubMed ID: 16108761
[TBL] [Abstract][Full Text] [Related]
13. Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNalpha2a shows earlier viral decline than peg-IFNalpha2b in combination therapy with ribavirin.
Fujino T; Nakamuta M; Aoyagi Y; Kohjima M; Satoh T; Fukuda M; Ishibashi H; Yatsuhashi H; Enjoji M
Med Sci Monit; 2011 Dec; 17(12):CR687-91. PubMed ID: 22129899
[TBL] [Abstract][Full Text] [Related]
14. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
Napoli N; Giannelli G; Antonaci A; Antonaci S
J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
[TBL] [Abstract][Full Text] [Related]
15. Early decline of the HCV core antigen can predict SVR in patients with HCV treated by Pegylated interferon plus ribavirin combination therapy.
Fujino T; Nakamuta M; Aoyagi Y; Fukuizumi K; Takemoto R; Yoshimoto T; Miyahara T; Harada N; Sakai H; Nakashima M; Enjoji M
J Dig Dis; 2009 Feb; 10(1):21-5. PubMed ID: 19236543
[TBL] [Abstract][Full Text] [Related]
16. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
Yu ML; Dai CY; Huang JF; Chiu CF; Yang YH; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
Hepatology; 2008 Jun; 47(6):1884-93. PubMed ID: 18508296
[TBL] [Abstract][Full Text] [Related]
17. Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients.
Baleriola C; Rawlinson WD; Dore GJ; Chaverot S; Stelzer-Braid S; Yoshihara M; Crawford D; Sievert W; McCaughan G; Weltman M; Cheng W; Rizkalla B; Dubois D; Thommes J; Roberts S
Antivir Ther; 2011; 16(2):173-80. PubMed ID: 21447866
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study.
Hansen N; Obel N; Christensen PB; Kjær M; Laursen AL; Krarup HB; Møller A; Schlichting P; Bukh J; Weis N;
BMC Infect Dis; 2011 Jun; 11():177. PubMed ID: 21693019
[TBL] [Abstract][Full Text] [Related]
19. Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment.
Ogawa E; Furusyo N; Toyoda K; Taniai H; Otaguro S; Kainuma M; Murata M; Sawayama Y; Hayashi J
BMC Gastroenterol; 2010 Apr; 10():38. PubMed ID: 20398383
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]